Skip to main navigation menu Skip to main content Skip to site footer

No. 3 (2026)

ORIRGINAL RESEARCH

Efficacy and safety of Aviandr® (maritupirdine) in adjustment disorders: Results of a multicenter observational study

https://doi.org/10.48612/psyph/av6m-ht53-ztkv

Published 2026-10-02

  • M.A. Kinkulkina
    • ,
  • B.A. Volel
    • ,
  • E.A. Smolyarchuk
    • ,
  • E.N. Morozov
    • ,
  • A.V. Ivaschenko
    • ,
  • I.A. Ivaschenko
    • ,
  • N.N. Ivanets
    • ,
  • T.I. Avdeeva
    • ,
  • Y.G. Tikhonova
    • ,
  • T.A. Izyumina
    • ,
  • P.A. Belyaeva
    • ,
  • V.A. Dedkova
    • ,
  • O.V. Izmailova
    • ,
  • D.A. Golovkina
    • ,
  • E.M. Goncharova
    • ,
  • D.S. Gorchakov
    • ,
  • A.A. Ivaschenko
    • ,
  • A.E. Morozov
    • ,
  • V.V. Tarasov

M.A. Kinkulkina
Sechenov First Moscow State Medical University

B.A. Volel
Sechenov First Moscow State Medical University

E.A. Smolyarchuk
Sechenov First Moscow State Medical University

E.N. Morozov
Sechenov First Moscow State Medical University

A.V. Ivaschenko
ChemDiv Inc.

I.A. Ivaschenko
OOO "Avineiro"

N.N. Ivanets
Sechenov First Moscow State Medical University

T.I. Avdeeva
Sechenov First Moscow State Medical University

Y.G. Tikhonova
Sechenov First Moscow State Medical University

T.A. Izyumina
Sechenov First Moscow State Medical University

P.A. Belyaeva
Psychotherapy Center "Podderzhka"

V.A. Dedkova
"Eco-Safety" Research Center

O.V. Izmailova
Samara State Medical University

D.A. Golovkina
Sechenov First Moscow State Medical University

E.M. Goncharova
Sechenov First Moscow State Medical University

D.S. Gorchakov
Sechenov First Moscow State Medical University

A.A. Ivaschenko
Lomonosov Moscow State University

A.E. Morozov
Sechenov First Moscow State Medical University

V.V. Tarasov
Sechenov First Moscow State Medical University

Abstract

Relevance. Adjustment disorders (AD) are highly prevalent in general medical practice and often present with somatic complaints. Despite the high need for pharmacotherapy, the evidence base for the use of psychotropic drugs in AD remains limited.

The Aim — to evaluate the efficacy and safety of Aviandr® (maritupirdine) for anxiety symptoms in the structure of AD in real-world clinical practice.

Materials and methods. A multicenter, open-label, observational post-registration study was conducted (N = 452). Patients received Aviandr® (40 mg/day) for
6 weeks, followed by a 2-week follow-up period. Efficacy was assessed using the SIGH-A scale, MADRS, MoCA, and VAS.

Results. By week 6, remission (SIGH-A ≤ 7) was achieved in 72.35 % of patients. A pronounced reduction in anxiety was observed as early as week 1 (a 27 %
decrease). Comparable reductions in psychic (75.13 %) and somatic (79.12 %) anxiety were recorded. The drug demonstrated high efficacy and a favorable safety
profile in elderly patients (≥ 65 years), peri- and postmenopausal women (n = 70), and individuals with comorbid somatic pathology. The overall incidence of adverse
events was 5.88 %.

Conclusion. Aviandr® has a rapid onset of action, reduces somatic manifestations of anxiety, and shows a favorable safety profile. The findings support its potential
use in patients with AD and comorbid somatic conditions.

Keywords

adjustment disorder, maritupirdine, Aviandr®, somatic anxiety, clinical practice, comorbidity, elderly patients

PDF (Русский)

References

  1. World Health Organization. International classification of diseases for mortality and morbidity statistics (11th Revision). – Geneva: World Health Organization, 2018. – URL: https://www.who.int/standards/classifications/classification-of-diseases (accessed May 14, 2026).
  2. Zelviene P., Kazlauskas E. Adjustment disorder: Current perspectives // Neuropsychiatric Disease and Treatment. – 2018. – Vol. 14. – Pp. 375–381. – https://doi.org/10.2147/NDT.S121072
  3. Maercker A., Brewin C.R., Bryant R.A. et al. Diagnosis and classification of disorders specifically associated with stress: Proposals for ICD-11 // World Psychiatry. – 2013. – Vol. 12 (3). – Pp. 198–206. – https://doi.org/10.1002/wps.20057
  4. O’Donnell M.L., Agathos J.A., Metcalf O. et al. Adjustment disorder: Current developments and future directions // International Journal of Environmental Research and Public Health. – 2019. – Vol. 16 (14). – Art. 2537. – https://doi.org/10.3390/ijerph16142537
  5. Cowansage K.P., Milligan T., Morgan M.A. et al. Treatments for adjustment disorder: A systematic review and meta-analysis of randomized controlled trials // Psychiatry Research. – 2025. – Vol. 353. – Art. 116739. – https://doi.org/10.1016/j.psychres.2025.116739
  6. Constantin D., Dinu E.A., Rogozea L. et al. Therapeutic interventions for adjustment disorder: A systematic review // American Journal of Therapeutics. – 2020. – Vol. 27 (4). – Pp. e375–e386. – https://doi.org/10.1097/MJT.0000000000001170
  7. Dobricki M., Komproe I.H., de Jong J.T. et al. Adjustment disorders after severe life-events in four postconflict settings // Social Psychiatry and Psychiatric Epidemiology. – 2010. – Vol. 45 (1). – Pp. 39–46. – https://doi.org/10.1007/s00127-009-0039-z
  8. McKenzie A., Burdett H., Croak B. et al. Adjustment disorder in the Armed Forces: A systematic review // Journal of Mental Health. – 2023. – Vol. 32 (5). – Pp. 962–984. – https://doi.org/10.1080/09638237.2022.2140792
  9. Arbus C., Hergueta T., Duburcq A. et al. Adjustment disorder with anxiety in old age: Comparing prevalence and clinical management in primary care and mental health care // European Psychiatry. – 2014. – Vol. 29 (4). – Pp. 233–238. – https://doi.org/10.1016/j.eurpsy.2013.04.002
  10. Mitchell A.J., Chan M., Bhatti H. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: A meta-analysis of 94 interview-based studies // The Lancet Oncology. – 2011. – Vol. 12 (2). – Pp. 160–174. – https://doi.org/10.1016/S1470-2045(11)70002-X
  11. Kroenke K., Spitzer R.L., Williams J.B.W. et al. The relationship between anxiety and depression with unexplained medical symptoms // Journal of Psychosomatic Research. – 2011. – Vol. 70 (5). – Pp. 425–431. – https://doi.org/10.1016/j.jpsychores.2010.04.002
  12. Casey P., Jabbar F., O’Leary E. et al. Suicidal behaviours in adjustment disorder and depressive episode // Journal of Affective Disorders. – 2015. – Vol. 174. – Pp. 441–446. – https://doi.org/10.1016/j.jad.2014.12.003
  13. Penninx B.W., Pine D.S., Holmes E.A. et al. Anxiety disorders // The Lancet. – 2021. – Vol. 397 (10277). – Pp. 914–927. – https://doi.org/10.1016/S0140-6736(21)00359-7
  14. American Geriatrics Society. 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults // Journal of the American Geriatrics Society. – 2023. – Vol. 71 (7). – Pp. 2052–2081. – https://doi.org/10.1111/jgs.18372
  15. Ivachtchenko A.V., Lavrovsky Y., Okun I. AVN-101: a multi-target drug candidate for the treatment of CNS disorders // Journal of Alzheimer’s Disease. – 2016. – Vol. 53 (2). – Pp. 583–620. – https://doi.org/10.3233/JAD-151146
  16. Смолярчук Е.А., Иващенко А.В., Иващенко А.А. и др. Мультимодальный механизм действия препарата маритупирдин и спектр потенциальных клинических эффектов // Современная терапия психических расстройств. – 2026. – № 2. – С. 75–84. – https://doi.org/10.48612/psyph/enbu-rbm4-r5bu
  17. Ivashchenko A.A., Morozova M.A., Vostokova N.V. et al. Safety and efficacy of aviandr in patients with generalized anxiety disorder: A multicenter, randomized, double-blind, placebo-controlled, dose-finding, pilot study // Journal of Psychiatric Research. – 2021. – Vol. 143. – Pp. 436–444. – https://doi.org/10.1016/j.jpsychires.2021.10.008
  18. Попова В.Б., Антонова Е.А., Хлябова П.М. и др. Эффективность и безопасность нового препарата Авиандр в лечении тревоги у пациентов с расстройством адаптации после перенесенной острой коронавирусной инфекции // Журнал неврологии и психиатрии имени С.С. Корсакова. – 2024. – Т. 124, № 7. – С. 131–138. – https://doi.org/10.17116/jnevro2024124071131
  19. Кинкулькина М.А., Данилов А.Б., Волель Б.А. и др. Эффективность и безопасность препарата АВИАНДР® у пациентов с тревожными состояниями после перенесенной коронавирусной инфекции (COVID-19): промежуточные результаты многоцентрового наблюдательного пострегистрационного исследования // Вестник неврологии, психиатрии и нейрохирургии. – 2025. – Т. 18, № 1. – С. 104–116. – https://doi.org/10.33920/med-01-2501-10
  20. Морозова М.А., Сафарова Т.П., Глускина Л.Я. и др. Двойное слепое плацебо-контролируемое исследование эффективности и переносимости препарата Авиандр® при лечении генерализованного тревожного расстройства // Современная терапия психических расстройств. – 2024. – № 3. – С. 2–16. – https://doi.org/10.21265/PSYPH.2024.82.78.001
  21. Hamilton M. The assessment of anxiety states by rating // British Journal of Medical Psychology. – 1959. – Vol. 32 (1). – Pp. 50–55. – https://doi.org/10.1111/j.2044-8341.1959.tb00467.x
  22. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change // British Journal of Psychiatry. – 1979. – Vol. 134 (4). – Pp. 382–389. – https://doi.org/10.1192/bjp.134.4.382
  23. Nasreddine Z.S., Phillips N.A., Bеdirian V. et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment // Journal of the American Geriatrics Society. – 2005. – Vol. 53 (4). – Pp. 695–699. – https://doi.org/10.1111/j.1532-5415.2005.53221.x
  24. Mahat-Shamir M., Pitcho-Prelorentzos S., Kagan M. et al. Adjustment disorder in the face of COVID-19 outbreak: The impact of death anxiety, media exposure, fear of contagion and hypochondriasis symptoms // Omega. – 2023. – Vol. 87 (4). – Pp. 1189–1206. – https://doi.org/10.1177/00302228211034372
  25. Greiner T., Haack B., Toto S. et al. Pharmacotherapy of psychiatric inpatients with adjustment disorder: Current status and changes between 2000 and 2016 // European Archives of Psychiatry and Clinical Neuroscience. – 2020. – Vol. 270 (1). – Pp. 107–117. – https://doi.org/10.1007/s00406-019-01058-1
  26. Fernаndez A., Mendive J.M., Salvador-Carulla L. et al. Adjustment disorders in primary care: Prevalence, recognition and use of services // The British Journal of Psychiatry. – 2012. – Vol. 201 (2). – Pp. 137–142. – https://doi.org/10.1192/bjp.bp.111.096305
  27. Nguyen N., Fakra E., Pradel V. et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: A double-blind controlled study in general practice // Human Psychopharmacology: Clinical and Experimental. – 2006. – Vol. 21 (3). – Pp. 139–149. – https://doi.org/10.1002/hup.814
  28. Stein D.J. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: A randomized controlled trial // Advances in Therapy. – 2015. – Vol. 32 (1). – Pp. 57–68. – https://doi.org/10.1007/s12325-015-0176-6
  29. Prеville M., Bossе C., Vasiliadis H.M. et al. Correlates of potentially inappropriate prescriptions of benzodiazepines among older adults: Results from the ESA study // Canadian Journal on Aging. – 2012. – Vol. 31 (3). – Pp. 313–322. – https://doi.org/10.1017/S0714980812000254
  30. Хасанова А. Применение антидепрессантов и риск падения у пациентов старшего возраста // Современная терапия психических расстройств. – 2022. – № 4. – С. 25–33. – https://doi.org/10.21265/PSYPH.2022.74.75.004

Downloads

Download data is not yet available.